Drug Profile
Research programme: protein phosphatase 5 inhibitors - SupremeCure Pharma
Alternative Names: PX - SupremeCure PharmaLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator SupremeCure Pharma
- Class Antineoplastics
- Mechanism of Action Protein phosphatase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cholangiocarcinoma; Liver cancer; Non-small cell lung cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Cholangiocarcinoma in Taiwan
- 28 May 2022 No recent reports of development identified for research development in Liver-cancer in Taiwan
- 28 May 2022 No recent reports of development identified for research development in Non-small-cell-lung-cancer in Taiwan